Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials.
Citation
Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. 2015, 350:h1269 BMJJournal
BMJ (Clinical research ed.)PubMed ID
25770113Abstract
To evaluate the relative risk of pulmonary disease among patients with psoriasis, psoriatic arthritis, and inflammatory bowel disease treated with methotrexate.Language
enISSN
1756-1833Collections
Related articles
- Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials.
- Authors: Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ
- Issue date: 2015 Oct
- Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials.
- Authors: Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ
- Issue date: 2016 May
- ACP Journal Club. Review: Methotrexate does not increase risk for lung disease in psoriasis, psoriatic arthritis, or IBD.
- Authors: Smith MD
- Issue date: 2015 Jul 21
- Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials.
- Authors: Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ
- Issue date: 2014 Apr
- Methotrexate for induction of remission in refractory Crohn's disease.
- Authors: McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG
- Issue date: 2012 Dec 12